Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 5 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Gastrointestinal Therapeutics in Asia-Pacific Market Introduction | 11 | 15 |
| Irritable Bowel Syndrome | 11 | 1 |
| Classification | 11 | 1 |
| Symptoms | 11 | 1 |
| Etiology | 11 | 1 |
| Pathophysiology | 12 | 1 |
| Diagnosis | 12 | 1 |
| Initial Assessment | 13 | 1 |
| Diagnostic Tests | 13 | 1 |
| Epidemiology | 14 | 1 |
| Prognosis | 14 | 1 |
| Treatment Options | 14 | 1 |
| Ulcerative Colitis | 15 | 1 |
| Classification | 15 | 2 |
| Symptoms | 17 | 1 |
| Etiology | 17 | 1 |
| Pathophysiology | 17 | 1 |
| Diagnosis | 18 | 1 |
| Epidemiology | 19 | 1 |
| Prognosis | 19 | 1 |
| Treatment Options | 19 | 2 |
| Crohn s Disease | 21 | 1 |
| Classification | 21 | 1 |
| Symptoms | 22 | 1 |
| Etiology | 22 | 1 |
| Pathophysiology | 23 | 1 |
| Diagnosis | 23 | 1 |
| Epidemiology | 24 | 1 |
| Prognosis | 24 | 1 |
| Treatment Options | 25 | 1 |
| Gastrointestinal Therapeutics in Asia-Pacific Market Marketed Products (Global) | 26 | 8 |
| Irritable Bowel Syndrome | 26 | 1 |
| Ulcerative Colitis | 26 | 1 |
| Crohn s Disease | 26 | 1 |
| Key Marketed Products | 27 | 1 |
| Amitiza | 27 | 1 |
| Humira | 28 | 1 |
| Remicade | 29 | 1 |
| Simponi | 30 | 1 |
| Cimzia | 31 | 1 |
| Tysabri | 32 | 2 |
| Gastrointestinal Therapeutics in Asia-Pacific Market Pipeline Analysis | 34 | 16 |
| Irritable Bowel Syndrome | 34 | 1 |
| Overall Pipeline | 34 | 2 |
| Pipeline Analysis by Molecule Type | 36 | 1 |
| Pipeline Analysis by Mechanism of Action | 37 | 2 |
| Ulcerative Colitis Pipeline | 39 | 1 |
| Overall Pipeline | 39 | 2 |
| Pipeline Analysis by Molecule Type | 41 | 1 |
| Pipeline Analysis by Mechanism of Action | 42 | 2 |
| Crohn s Disease Pipeline | 44 | 1 |
| Overall Pipeline | 44 | 2 |
| Pipeline Analysis by Molecule Type | 46 | 1 |
| Pipeline Analysis by Mechanism of Action | 47 | 2 |
| Promising Drug Candidates in the Pipeline | 49 | 1 |
| GSK-1605786 | 49 | 1 |
| MLN0002 | 49 | 1 |
| EMD-61753 | 49 | 1 |
| Gastrointestinal Therapeutics in Asia-Pacific Market Market Forecast to 2019 | 50 | 11 |
| Asia-Pacific Markets | 50 | 1 |
| Treatment Usage Patterns | 50 | 1 |
| Annual Cost of Therapy | 50 | 1 |
| Market Size | 50 | 2 |
| Australia | 52 | 1 |
| Treatment Usage Patterns | 52 | 1 |
| Annual Cost of Therapy | 52 | 1 |
| Market Size | 52 | 2 |
| India | 54 | 1 |
| Treatment Usage Patterns | 54 | 1 |
| Annual Cost of Therapy | 54 | 1 |
| Market Size | 54 | 2 |
| China | 56 | 1 |
| Treatment Usage Patterns | 56 | 1 |
| Annual Cost of Therapy | 56 | 1 |
| Market Size | 56 | 2 |
| Japan | 58 | 1 |
| Treatment Usage Patterns | 58 | 1 |
| Annual Cost of Therapy | 58 | 1 |
| Market Size | 58 | 2 |
| Drivers and Barriers | 60 | 1 |
| Drivers | 60 | 1 |
| Increase in Prevalence due to Lifestyle | 60 | 1 |
| Expected Launch of Costly Drugs | 60 | 1 |
| Highest Populated Countries | 60 | 1 |
| Barriers | 60 | 1 |
| Reduced Prescription of Branded Medicine | 60 | 1 |
| Low Diagnosis Rate | 60 | 1 |
| Patent Expiries of Major Marketed Drugs | 60 | 1 |
| Gastrointestinal Therapeutics in Asia-Pacific Market Deals and Strategic Consolidations (Global) | 61 | 6 |
| Deals Analysis | 61 | 2 |
| Major Co-Development Deals | 63 | 1 |
| AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide | 64 | 1 |
| Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies | 64 | 1 |
| Galapagos and AbbVie Extend GLPG0634 Development Agreement to Include Crohn's Disease | 64 | 1 |
| Major Licensing Deals | 65 | 1 |
| AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3 Inhibitor Program | 66 | 1 |
| Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin | 66 | 1 |
| GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx | 66 | 1 |
| Gastrointestinal Therapeutics in Asia-Pacific Market Appendix | 67 | 20 |
| Market Definitions | 67 | 1 |
| Abbreviations | 67 | 2 |
| Sources | 69 | 2 |
| All Pipeline Drugs by Phase | 71 | 7 |
| Discovery | 71 | 1 |
| Preclinical | 71 | 1 |
| IND/CTA-filed | 72 | 1 |
| Phase I | 73 | 1 |
| Phase II | 74 | 2 |
| Phase III | 76 | 1 |
| Pre-Registration | 76 | 1 |
| Undisclosed | 77 | 1 |
| Market Forecasts to 2019 | 77 | 6 |
| Asia-Pacific Markets | 77 | 1 |
| Irritable Bowel Syndrome | 77 | 1 |
| Ulcerative Colitis | 78 | 1 |
| Crohn s Disease | 78 | 1 |
| Australia | 78 | 1 |
| Irritable Bowel Syndrome | 78 | 1 |
| Ulcerative Colitis | 79 | 1 |
| Crohn s Disease | 79 | 1 |
| India | 79 | 1 |
| Irritable Bowel Syndrome | 79 | 1 |
| Ulcerative Colitis | 80 | 1 |
| Crohn s Disease | 80 | 1 |
| China | 80 | 1 |
| Irritable Bowel Syndrome | 80 | 1 |
| Ulcerative Colitis | 81 | 1 |
| Crohn s Disease | 81 | 1 |
| Japan | 81 | 1 |
| Irritable Bowel Syndrome | 81 | 1 |
| Ulcerative Colitis | 82 | 1 |
| Crohn s Disease | 82 | 1 |
| Research Methodology | 82 | 5 |
| Coverage | 82 | 1 |
| Secondary Research | 83 | 1 |
| Primary Research | 83 | 1 |
| Therapeutic Landscape | 83 | 2 |
| Market Size by Geography | 85 | 1 |
| Geographical Landscape | 86 | 1 |
| Pipeline Analysis | 86 | 1 |
| Expert Panel Validation | 86 | 1 |
| Contact Us | 86 | 1 |
| Disclaimer | 86 | 1 |
